ENLV — Enlivex Therapeutics Share Price
0.000.00%
Last trade - 00:00- $27.99m
- $4.56m
- 20
- 34
- 17
- 13
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.93 | ||
| Price to Tang. Book | 0.93 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -95.53% | ||
| Return on Equity | -66.88% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Directors
- Oren Hershkovitz CEO (44)
- Shai Novik VCH (55)
- Dror Mevorach FDR (65)
- Shachar Shlosberger CFO (44)
- Baruch Halpert DRC (54)
- Bernhard Kirschbaum DRC (62)
- Sangwoo Lee DRC (49)
- Brian Schwartz DRC (49)
- Michel Habib IND (54)
- Gili Hart IND (46)
- Abraham Havron IND (73)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- January 22nd, 2012
- Public Since
- July 30th, 2014
- No. of Shareholders
- 72
- No. of Employees
- 49
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 20,658,555
- Address
- 14 Einstein St., NESS-ZIONA, 7403618
- Web
- https://www.enlivex.com/
- Phone
- +972 86623301
- Auditors
- Yarel Partners
Upcoming Events for ENLV
Similar to ENLV
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Enlivex Therapeutics share price?
As of Today at 20:29 UTC, shares in Enlivex Therapeutics are trading at $1.36. This share price information is delayed by 15 minutes.
How has the Enlivex Therapeutics share price performed this year?
Shares in Enlivex Therapeutics last closed at $1.36 and the price had moved by -49.82% over the past 365 days. In terms of relative price strength the Enlivex Therapeutics share price has underperformed the S&P500 Index by -60.07% over the past year.
What are the analyst and broker recommendations for Enlivex Therapeutics?
The overall consensus recommendation for Enlivex Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Enlivex Therapeutics dividend yield?
Enlivex Therapeutics does not currently pay a dividend.
Does Enlivex Therapeutics pay a dividend?
Enlivex Therapeutics does not currently pay a dividend.
When does Enlivex Therapeutics next pay dividends?
Enlivex Therapeutics does not currently pay a dividend.
How do I buy Enlivex Therapeutics shares?
To buy shares in Enlivex Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Enlivex Therapeutics?
As of the previous close price of $1.36, shares in Enlivex Therapeutics had a market capitalisation of $28.10m.
Where are Enlivex Therapeutics shares listed?
Here are the trading details for Enlivex Therapeutics:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ENLV
What kind of share is Enlivex Therapeutics?
Based on an overall assessment of its quality, value and momentum Enlivex Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Enlivex Therapeutics share price forecast for 2024?
The analyst consensus target price for shares in Enlivex Therapeutics is $6.00. That is 341.18% above the last closing price of $1.36.
Analysts covering Enlivex Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.81 for the next financial year.
What is the trend in the Enlivex Therapeutics share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Enlivex Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -59.3%.
As of the last closing price of $1.36, shares in Enlivex Therapeutics were trading -38.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Enlivex Therapeutics PE Ratio?
The Enlivex Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.36.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Enlivex Therapeutics?
Enlivex Therapeutics' management team is headed by:
- Oren Hershkovitz - CEO
- Shai Novik - VCH
- Dror Mevorach - FDR
- Shachar Shlosberger - CFO
- Baruch Halpert - DRC
- Bernhard Kirschbaum - DRC
- Sangwoo Lee - DRC
- Brian Schwartz - DRC
- Michel Habib - IND
- Gili Hart - IND
- Abraham Havron - IND